Reported about 1 month ago
AbbVie Inc. surpassed revenue expectations for the fourth quarter and increased its sales forecast for new drugs Skyrizi and Rinvoq by $4 billion, even as sales of the immunosuppressant Humira plummeted by 49%. Analyst Evan Seigerman discussed AbbVie's ongoing drug research efforts, particularly in oncology and neuroscience, amid recent challenges. Additionally, discussions surrounding Robert F. Kennedy Jr.'s HHS confirmation hearing may influence pharmaceutical stocks, particularly concerning the critical FDA leadership.
Source: YAHOO